University Health Network, Toronto: Leukemia, Myeloid trials
The registry lists 13 Leukemia, Myeloid studies with University Health Network, Toronto as lead sponsor. 1 are open to participants now and 1 have results posted.
Phase 1 7Phase 2 5Phase 4 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Myeloproliferative Neoplasms (MPNs) Patient RegistryRecruitingNCT02760238
- Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction ChemotherapyCompletedNCT01334086Phase 2Results posted
- Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid LeukemiaCompletedNCT03027102Phase 1
- Allogeneic SCT for CML, TKI Failure After TKI FailureStatus unknownNCT02172365
- Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-LeukemiaCompletedNCT01914484Phase 1/2
- An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction ChemotherapyCompletedNCT01446081Phase 2
- Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid LeukemiaCompletedNCT01332786Phase 1
- Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid LeukemiaTerminatedNCT01222143Phase 1/2
- Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic MalignancyCompletedNCT00990587Phase 1
- Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological MalignancyTerminatedNCT00963495Phase 1
- Maintenance Therapy in Acute Myeloid Leukemia (AML) PatientsCompletedNCT00957385Phase 2
- Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on ImatinibTerminatedNCT00461929Phase 4
- Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00101153Phase 1